Multifunctional immune-modulatory protein HLA-E identified in classical Hodkin lymphoma: Possible implications

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F12%3A%230001845" target="_blank" >RIV/65269705:_____/12:#0001845 - isvavai.cz</a>

Result on the web

<a href="http://dx.doi.org/10.1016/j.prp.2011.11.004" target="_blank" >http://dx.doi.org/10.1016/j.prp.2011.11.004</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.prp.2011.11.004" target="_blank" >10.1016/j.prp.2011.11.004</a>

Result language

angličtina

Original language name

Multifunctional immune-modulatory protein HLA-E identified in classical Hodkin lymphoma: Possible implications

Original language description

Although the role of the non-classical human leukocyte antigen E (HLA-E) was originally thought to be limited to the development of a maternal tolerance to a semiallogeneic fetal graft, it is now known that HLA-E exerts multiple immunoregulatory functions. The significance of the presence of HLA-E in neoplastic cells and/or background microenvironment cells in classical Hodgkin lymphoma (cHL) is not well characterized. In our study, we evaluated the presence of HLA-E in both neoplastic and background cells in 40 cases of cHL. We found HLA-E in both neoplastic and background cells. There was a positive statistical correlation between the expression of HLA-E in neoplastic cells and the clinical stage of the disease, which indicates an immune-tolerogenicproperty of this multiple-purpose molecule. The presence of HLA-E in background cells seems to be prognostically neutral but its significance still needs to be determined. The mechanisms regulating the immunopathology of cHL neoplastic ce

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

<a href="/en/project/NS9871" target="_blank" >NS9871: Optimized dendritic cells loaded with universal tumor antigens as a potent individualized cancer vaccine</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2012

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Pathology, research and practice

ISSN

0344-0338

e-ISSN

—

Volume of the periodical

208

Issue of the periodical within the volume

1

Country of publishing house

DE - GERMANY

Number of pages

5

Pages from-to

45-49

UT code for WoS article

000300602900007

EID of the result in the Scopus database

—